Barbara Schmidt
Department of Clinical Epidemiology and Biostatistics
McMaster University
Hamilton
Canada
Name/email consistency: high
- Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. Schmidt, B., Anderson, P.J., Doyle, L.W., Dewey, D., Grunau, R.E., Asztalos, E.V., Davis, P.G., Tin, W., Moddemann, D., Solimano, A., Ohlsson, A., Barrington, K.J., Roberts, R.S. JAMA (2012)
- Long-term effects of caffeine therapy for apnea of prematurity. Schmidt, B., Roberts, R.S., Davis, P., Doyle, L.W., Barrington, K.J., Ohlsson, A., Solimano, A., Tin, W. N. Engl. J. Med. (2007)
- Caffeine therapy for apnea of prematurity. Schmidt, B., Roberts, R.S., Davis, P., Doyle, L.W., Barrington, K.J., Ohlsson, A., Solimano, A., Tin, W. N. Engl. J. Med. (2006)
- Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP). Schmidt, B., Roberts, R.S., Fanaroff, A., Davis, P., Kirpalani, H.M., Nwaesei, C., Vincer, M. J. Pediatr. (2006)
- Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial. Schmidt, B. Biol. Neonate (2005)
- Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms. Schmidt, B., Asztalos, E.V., Roberts, R.S., Robertson, C.M., Sauve, R.S., Whitfield, M.F. JAMA (2003)
- Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. Schmidt, B., Davis, P., Moddemann, D., Ohlsson, A., Roberts, R.S., Saigal, S., Solimano, A., Vincer, M., Wright, L.L. N. Engl. J. Med. (2001)